Findings

What do systematic reviews say?

358 questions · 360 findings · 31 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 86 · 23.9%GRADE not reported 15 · 4.2%Very low 40 · 11.1%Low 117 · 32.5%Moderate 90 · 25%High 12 · 3.3%

Tranexamic acid vs placebo

Red cell transfusion requirements (mL) ( · people aged 18 and over undergoing vascular surgery

The review found no eligible studies for this question.

1 finding from 1 review

Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tranexamic acid vs placebo

All‐cause mortality up to 30 days · people aged 18 and over undergoing vascular surgery

1 finding from 1 review

Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Very low

Tranexamic acid vs placebo

Risk of receiving any allogeneic blood product (data only available for intraoperative blood product use) · people aged 18 and over undergoing vascular surgery

It is very uncertain whether summary of findings: Tranexamic acid changes risk of receiving any allogeneic blood product (data only available… compared with placebo (very low certainty).

1 finding from 1 review

Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and… 2023 · Cochrane Headline outcomes only
RR 0.66 [0.11, 3.95]
1 study · 100 participants
Very low

Tranexamic acid vs placebo

Risk of reoperation or repeat procedure for bleeding within 7 days · people aged 18 and over undergoing vascular surgery

It is very uncertain whether summary of findings: Tranexamic acid changes risk of reoperation or repeat procedure for bleeding within 7 days compared with placebo (very low certainty).

1 finding from 1 review

Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and… 2023 · Cochrane Headline outcomes only
RR 0.33 [0.01, 7.99]
1 study · 100 participants
Very low

Tranexamic acid vs placebo

Risk of a thrombotic/thromboembolic event (MI, CVA, DVT, PE) · people aged 18 and over undergoing vascular surgery

Summary of findings: Tranexamic acid showed no clear difference in risk of a thrombotic/thromboembolic event (MI, CVA, DVT, PE) compared with placebo (low certainty).

1 finding from 1 review

Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and… 2023 · Cochrane Headline outcomes only
RR 1.1 [0.88, 1.36]
1 study · 1360 participants
Low

Anticoagulant vs placebo or no treatment

All‐cause mortality · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.36 [0.04, 3.61]
5 studies · 1777 participants
Low

Anticoagulant vs placebo or no treatment

Venous thromboembolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant probably leads to lower venous thromboembolism compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.36 [0.16, 0.85]
4 studies · 1259 participants
Moderate

Anticoagulant vs placebo or no treatment

Major bleeding · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in major bleeding compared with placebo or no treatment (low certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.36 [0.01, 8.78]
5 studies · 1777 participants
Low

Anticoagulant vs placebo or no treatment

Deep vein thrombosis · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in deep vein thrombosis compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 1.02 [0.3, 3.46]
3 studies · 1009 participants
Moderate

Anticoagulant vs placebo or no treatment

Pulmonary embolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant probably leads to lower pulmonary embolism compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.25 [0.08, 0.79]
3 studies · 1009 participants
Moderate

Anticoagulant vs placebo or no treatment

Need for hospitalisation · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in need for hospitalisation compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 1.01 [0.59, 1.75]
4 studies · 1459 participants
Moderate

Anticoagulant vs placebo or no treatment

Adverse events (minor bleeding) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in adverse events (minor bleeding) compared with placebo or no treatment (low certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 2.46 [0.9, 6.72]
5 studies · 1777 participants
Low

Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo

Recurrent VTE · people requiring treatment for chronic DVT

Chronic DVT ‐ antiplatelet agents plus BMP may leads to lower recurrent VTE ‐ early, intermediate and long term compared with BMP plus placebo (low certainty).

1 finding from 1 review

Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
RR 0.65 [0.43, 0.96]
4 studies · 901 participants
Low

Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo

Major bleeding · people requiring treatment for chronic DVT

Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in major bleeding compared with BMP plus placebo (moderate certainty).

1 finding from 1 review

Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
RR 0.98 [0.29, 3.34]
1 study · 583 participants
Moderate

Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo

Pulmonary embolism · people requiring treatment for chronic DVT

Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in pulmonary embolism (fatal/non‐fatal) compared with BMP plus placebo (moderate certainty).

1 finding from 1 review

Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
RR 0.52 [0.23, 1.14]
1 study · 583 participants
Moderate

Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo

Mortality ‐ intermediate and long term · people requiring treatment for chronic DVT

Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in mortality ‐ intermediate and long term compared with BMP plus placebo (moderate certainty).

1 finding from 1 review

Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
RR 0.48 [0.21, 1.06]
3 studies · 649 participants
Moderate

Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo

Post‐thrombotic syndrome · people requiring treatment for chronic DVT

The review found no eligible studies for this question.

1 finding from 1 review

Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo

Adverse events · people requiring treatment for chronic DVT

Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in adverse events compared with BMP plus placebo (moderate certainty).

1 finding from 1 review

Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
RR 1.57 [0.34, 7.19]
2 studies · 621 participants
Moderate

Avoralstat vs placebo

Risk of HAE attacks (during · children or adults with Types I or II HAE

Avoralstat showed no clear difference in risk of HAE attacks (during compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.99 [0.92, 1.06]
1 study · 110 participants
Moderate

Berotralstat vs placebo or active control

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found